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BACKGROUND: Many heart diseases can result in reduced pumping capacity of the heart muscle. A mismatch between 
ATP demand and ATP production of cardiomyocytes is one of the possible causes. Assessment of the relation between 
myocardial ATP production (MVATP) and cardiac workload is important for better understanding disease development and 
choice of nutritional or pharmacologic treatment strategies. Because there is no method for measuring MVATP in vivo, the use 
of physiology-based metabolic models in conjunction with protein abundance data is an attractive approach.
METHOD: We developed a comprehensive kinetic model of cardiac energy metabolism (CARDIOKIN1) that recapitulates 
numerous experimental findings on cardiac metabolism obtained with isolated cardiomyocytes, perfused animal hearts, and 
in vivo studies with humans. We used the model to assess the energy status of the left ventricle of healthy participants 
and patients with aortic stenosis and mitral valve insufficiency. Maximal enzyme activities were individually scaled by 
means of protein abundances in left ventricle tissue samples. The energy status of the left ventricle was quantified by the 
ATP consumption at rest (MVATP[rest]), at maximal workload (MVATP[max]), and by the myocardial ATP production reserve, 
representing the span between MVATP(rest) and MVATP(max).
RESULTS: Compared with controls, in both groups of patients, MVATP(rest) was increased and MVATP(max) was decreased, 
resulting in a decreased myocardial ATP production reserve, although all patients had preserved ejection fraction. 
The variance of the energetic status was high, ranging from decreased to normal values. In both patient groups, the 
energetic status was tightly associated with mechanic energy demand. A decrease of MVATP(max) was associated with 
a decrease of the cardiac output, indicating that cardiac functionality and energetic performance of the ventricle are 
closely coupled.
CONCLUSIONS: Our analysis suggests that the ATP-producing capacity of the left ventricle of patients with valvular dysfunction 
is generally diminished and correlates positively with mechanical energy demand and cardiac output. However, large 
differences exist in the energetic state of the myocardium even in patients with similar clinical or image-based markers of 
hypertrophy and pump function.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT03172338 and NCT04068740.
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In recent years, numerous studies have firmly estab-lished metabolic derangement as a cardinal feature of the pathophysiology of heart diseases.1–5 Although 
changes in cardiac metabolism are understood to be an 
underlying component in almost all cardiac myopathies, 
the potential contribution of myocardial energy metabo-
lism to the reduction of cardiac performance is not fully 
understood.6 As early as 1939, Herrmann and Decherd 
Jr7 proposed that the failing heart is an energy-starved 
engine that has run out of fuel. Several decades later, this 
concept has been reaffirmed,3 primarily in light of find-
ings that in the failing heart, the gene expression of key 
proteins involved in cardiac energy metabolism is down-
regulated (see examples)8,9 and so is the level of central 
metabolic enzymes (eg, creatine kinase)10 and of cardiac 
energy-rich phosphates (ATP, CrP), as established by 31P 
magnetic resonance spectroscopy in vivo.11,12 Although 
these findings are suggestive for a mismatch between 
ATP demand and ATP supply, they do not permit assess-
ment of the degree of mismatch.
A common cause of cardiac dysfunction is valvular 
heart disease. The most frequent types of valve disease 
are aortic stenosis (AS) and mitral valve insufficiency 
(MVI), which expose the heart to long-term pressure 
or volume overload, respectively. Chronic pressure or 
volume overload trigger cardiac remodeling, leading 
to specific forms of myocardial hypertrophy. Pressure 
overload typically results in eccentric myocardial hyper-
trophy with wall thickness increase, whereas volume 
overload is dominated by concentric forms with increase 
of ventricular chamber volumes. Some patients tolerate 
the overload condition well for years, whereas others 
quickly change from compensated to decompensated 
heart failure despite similar cardiac pump function char-
acteristics. Therefore, it is of particular importance in 
the clinic to be able to predict the risk for transition from 
compensated to decompensated heart failure as accu-
rately as possible. This would include better knowledge 
about the metabolic status of the myocardium in heart 
diseases. Using cardiac magnetic resonance imaging 
and 31P magnetic resonance spectroscopy, Peterzan 
et al.13 addressed whether reduced delivery of ATP 
from mitochondria to the myosin ATPase by the cre-
atine kinase shuttle may explain why some (but not all) 
patients with severe AS develop otherwise unexplained 
reduced left ventricular (LV) ejection fraction. Their data 
do not provide evidence for a significant difference in 
the creatine kinase flux of patients with cardiac dys-
function. This finding raises the question whether it is 
the gradual reduction in the myocardial ATP production 
capacity (MVATP) that parallels the deterioration of the 
LV systolic function that is at issue. The problem with 
testing this hypothesis is that no method is available to 
measure the ATP production rate MVATP in vivo. The aim 
of this work was to develop a method allowing assess-
ment of the capability of the LV to increase MVATP in 
response to an increase in ATP demand.
On the basis of our network reconstruction of the 
metabolic network of the cardiomyocyte14 and previous 
modeling work on metabolic subsystems,15–18 we estab-
lished a complex physiology-based mathematical model 
of the myocardial energy metabolism. The model encom-
passes all pathways along which the possible energy-
Clinical Perspective
What Is New?
• We developed CARDIOKIN1, a novel comprehen-
sive molecular-resolved kinetic model of central car-
diac metabolism.
• CARDIOKIN1 enables new insights into regula-
tory principles of cardiac metabolism and allows 
patient-specific evaluation of metabolic capacities 
on the basis of proteomics data.
• We applied the method in patients who had sig-
nificant change in cardiac workload owing to aortic 
and mitral valve diseases.
What Are the Clinical Implications?
• Common heart valve diseases, such as aortic ste-
nosis and mitral regurgitation, lead to significant 
impairment in cardiac metabolic capacity.
• Metabolic capacities have a significant correlation 
with biomechanical measures such as myocardial 
power and cardiac output but can vary consider-
ably between individual patients, contributing to 
understanding why some patients develop heart 
failure over time, whereas others with similar hemo-
dynamic conditions do not.
• Individual metabolic capacities are associated with 
postoperative outcomes and may be a helpful prog-
nostic marker.
Nonstandard Abbreviations and Acronyms
AS aortic stenosis
BCAA branched-chain amino acid
BP blood pressure




MAPR myocardial ATP production reserve
MVI mitral valve insufficiency
MVATP myocardial ATP production capacity
MVATP(max)  myocardial ATP consumption at maxi-
mal workload
MVATP(rest) myocardial ATP consumption at rest
MVo2 myocardial oxygen consumption
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delivering substrates glucose, long-chain fatty acids, 
ketone bodies (KBs), acetate, and branched-chain amino 
acids (BCAAs) are used. As in our previous model-based 
studies on liver metabolism,19 we used the proteomics-
based abundance of metabolic enzymes in cardiac tissue 
to generate individualized metabolic models of cardiac 
energy metabolism. Applying this approach to the LV of 
controls and patients with MVI and AS, we tested the 
hypothesis that despite overall preserved systolic func-
tion, the ATP production capacity of the LV is reduced 
and correlates positively with mechanic energy demand 
and cardiac output.
METHODS
The analytic methods (model equations) are available in the 
Supplemental Materials for other researchers for purposes of 
replicating the procedure. Patients’ proteomics data will not be 
made available to other researchers.
Patient Characteristics
We investigated 75 human LV myocardial biopsies. Myocardial 
samples from the LV septum were collected during surgical 
aortic or mitral valve replacement from 41 patients with AS and 
17 patients with MVI. Patient characteristics are described in 
the Table. For the controls (n = 17), samples were taken from 
44 ≥15-year-old donors without cardiac diseases but whose 
hearts were not used for transplantation. All samples were fro-
zen immediately in liquid nitrogen until further processing.
The study protocol was in agreement with the principles 
outlined in the Declaration of Helsinki and was approved by 
the Medical Ethics Review Committee. All patients gave written 
informed consent before inclusion.
Quantitative Proteomics of Tissue Samples
LV septum biopsies were extracted at time of surgery, fro-
zen directly in liquid nitrogen, and kept at –80°C. For protein 
extraction, biopsies were lysed in 200 µL lysis buffer (2% 
SDS, 50 mM ammonium bicarbonate buffer, and EDTA-free 
protease inhibitor cocktail [Complete; Roche]) and homoge-
nized using FastPrep-24 5G Homogenizer (MP Biomedicals; 
10 cycles of 20 seconds with 5-second pause). After heating 
for 5 minutes at 95°C and 5 freeze–thaw cycles, Benzonase 
(25 U; Merck) was added for 30 minutes and lysates were 
clarified by centrifugation at 16 000 g for 40 minutes. A 
total of 100 µg protein per sample was processed further 
using the SP3 clean-up and digestion protocol as previously 
described.20 Briefly, each sample was reduced with 10 mM 
dithiothreitol (Sigma), followed by alkylation with 40 mM chlo-
roacetamide (Sigma) and quenching with 20 mM dithiothreitol 
(Sigma). Next, 1 mg beads and acetonitrile (70% final con-
centration) were added to each sample and after 20 minutes 
of incubation, bead-bound protein was washed with 70% 
ethanol and 100% acetonitrile. Then, 2 µg sequence-grade 
Trypsin (Promega) and 2 µg LysC (Wako) in 50 mM HEPES 
(pH 8) were added. After overnight incubation at 37°C, pep-
tides were collected, acidified with trifluoroacetic acid, and 
cleaned up using the StageTips protocol.21
Heart Reference Sample for Matching Library
A peptide mix for each experimental group (control, AS, and 
MVI) was generated by collecting 10 µg peptides from each 
individual sample belonging to the corresponding group. Equal 
peptide amounts from each group mixture were combined, 
fractionated into 96 fractions by basic reversed-phase chroma-
tography (XBridge C18 4.6 mm × 250 mm column [Waters, 3.5 
µm bead size]; Agilent 1290 high-performance liquid chroma-
tography instrument; 90 minutes gradient; flow rate 1 mL/min), 
and pooled into 26 equal interval fractions for further analyses.
Liquid Chromatography With Tandem Mass 
Spectrometry Analyses
Peptides were separated by reversed-phase chromatography 
(20 cm column; 75 µm inner diameter, ReproSil-Pur C18-AQ; 
1.9 µm, Dr Maisch GmbH) using a 200-minute gradient (flow 
rate 250 nL/min) on a high-performance liquid chromatogra-
phy system (ThermoScientific). Measurements were performed 
on an Orbitrap Fusion (individual samples) or Q Exactive HF-X 
Orbitrap instrument (reference sample; ThermoScientific) using 
data-dependent acquisition. Each sample was measured twice 
and replicates were joined for data analysis. Data were analyzed 
using MaxQuant (v1.6.2.6) and a decoy human UniProt database 
(2019-01).22 Variable modifications of oxidation (M), N-terminal 
acetylation, deamidation (N, Q), and fixed modification of carb-
amidomethyl cysteine were selected. The false discovery rate was 
set to 1% for peptide and protein identification. Unique and razor 
peptides were considered for quantification. Match between runs 
and label-free quantification algorithm were applied.
Description of the Mathematical Model 
(CARDIOKIN1)
For quantification of the metabolic changes caused by the 
abundance changes of metabolic enzymes, we developed a 
mathematical model of the cardiac energy metabolism, which 
comprises all pathways involved in the catabolism of the energy-
delivering substrates glucose, lactate, fatty acids, KBs, and 
BCAAs, as well as the synthesis of endogenous energy stores 
(glycogen, triacylglycerol; Figure 1). The model also takes into 
account the short-term regulation of metabolic enzymes and 
transporters by the hormones insulin and catecholamines and 
key electrophysiologic processes at the inner mitochondrial 
membrane including generation of the proton gradient by the 
respiratory chain, synthesis of ATP by FoF1-ATPase, and mem-
brane transport of various ions.
The time course of model variables (concentration of 
 metabolites and ions) is governed by first-order differential 
equations. Time variations of small ions are modeled by kinetic 
equations of the Goldman-Hodgkin-Katz type as used in our 
previous work.23 The rate laws for enzymes and membrane 
transporters were either taken from the literature or con-
structed on the basis of published experimental data for the 
mammalian heart. The used rate laws take into account the 
regulation of enzymes and transporters by reaction substrates 
and products, allosteric effectors, and reversible phosphoryla-
tion as compiled by biochemists during decades of enzymatic 
research. Supplement S1 contains all kinetic equations and 
model parameters sorted by individual pathways. For each 
kinetic parameter value, we indicated the experimental source.
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Model Calibration for Individual Hearts
Among the kinetic parameters of the enzymatic rate laws (bind-
ing constants of ligands, cooperativity indices), only Vmax, repre-
senting the maximal activity of an enzyme/transporter, may vary 
among individual LVs as the value of this parameter is propor-
tional to the enzyme abundance: Vmax = kcat • E, with kcat being 
the turnover rate of a single enzyme and E the enzyme con-
centration. Exploiting this simple relationship, we used the pro-
teomics-derived protein profiles of enzymes and  transporters 
for model calibration by computing the maximal activities (Vmax) 








where Econtrol is the average protein intensity of the enzyme 
in the group of control hearts and E subject  is the protein con-
centration of the enzyme in the individual (control or patient). 
The maximal activities vnormalmax of the reference model for the 
average normal heart were obtained by fitting of the model to 
experimental data (Table S2). Relation (1) follows from the fact 
that the maximal enzyme activity is proportional to the abun-
dance of the protein.
Energetic Capacities of Controls and Patients 
With Valve Diseases
We used the model to compute the specific uptake rates of sub-
strates and the specific ATP production rate at rest, MVATP(rest), 
and at maximal ATP workload, MVATP(max), for the LV of controls 
(n=17) and patients with MVI (n=17) or AS (n=41). As a third 
parameter to characterize the capacity of the LV to increase ATP 
production with increasing workload, we used the span between 
MVATP(max) and MVATP(rest), which we refer to as myocardial 
ATP production reserve (MAPR = MVATP[max] – MVATP[rest]). 
In the following, we distinguish among specific energy param-
eters MVATP(rest), MVATP(max), and MAPR quantifying the ener-
getic capacity per mass unit of the LV (given in µmol/g/h) and 
total energy parameters tMVATP(rest), tMVATP(max), and tMAPR 
quantifying the energetic capacity of the LV (given in mmol/h; ie, 
tMVATP[rest] = MVATP[rest] × LV mass/1000).
The computations were performed for a normal postab-
sorptive state (overnight fast) characterized by the following 
 metabolite and hormone concentrations: glucose 5.8 mM,24 
fatty acids 0.5 mM,25 lactate 0.8 mM,24 glutamine 0.5 mM,26,27 
valine 0.2 mM,26,27 leucine 0.15 mM,26,27 isosleucine 0.06 
mM,26,27 β-hydroxybutyrate 0.08 mM,28,29 and acetoacetate 0.04 
mM.30 The concentration of catecholamines at rest was 0.75 
nM31,32 and increased with growing workload (see Supplement 
S2, including Figures S1–S4).
The myocardial ATP consumption of the stationary rest-
ing state, MVATP(rest), was chosen in a way that the computed 
myocardial oxygen consumption (MVo2) was identical with 
the participant’s MVo2, which we estimated by the 2-factor 
approximation33
MV HR BPO2 = γ · ·  (2)
using heart rate (HR) and peak systolic blood pressure (BP) 
and γ as a proportionality factor. Resting MVo2 of normal hearts 
was found in the range of 0.8 to 1.2 mL/min/g.2,4,34 Thus, with 
a mean MVo2 of 0.1 mL/min/g, HR of 70/min, and normal BP 
of 125 mm, we set γ to 1.143 × 10–5 mL/mm Hg/g.
The metabolic response of the ventricle to an additional 
workload (pacing) was evaluated by computing the temporal 
changes of the metabolic state elicited by an increase of the 
ATP consumption rate above the resting value. The ATP con-
sumption rate was modeled by a generic hyperbolic rate law
v k
ATP




(Supplement S1). The parameter kload was stepwise increased 
until MVATP converged to the maximum: MVATP(max).
To evaluate the mechanical burden of the heart, we calcu-
lated the internal myocardial power, which describes the energy 
required for cardiac contraction for the individual hearts (see 
methods used in Lee et al35).
Table. Patient Characteristics
Characteristics and preoperative 
function measures AS MVI P value
Age at surgery, y 68±9 60±14 0.032
BMI 28±4 27±3 0.343
Female sex 23 (56) 6 (35) 0.414
NYHA functional classification, 
stage I/II/III/IV
5/17/15/1 2/7/6/2 0.593
Systolic blood pressure, mm Hg 140±19 131±16 0.123
Diastolic blood pressure, mm Hg 74±11 75±13 0.675
EDVI, mL/m2 73±17 108±34 <0.001
ESVI, mL/m2 30±11 40±14 0.015
EF, % 60±7 62±9 0.048
CI, L/min/m2 3±1 5±2 <0.001
CO, L/min 6±2 9±4 <0.001
Internal myocardial power 13±7 13±5 1
Myocardial mass (indexed), g/m2 71±20 67±15 0.484
Mean pressure gradient aortic valve, 
mm Hg
56±15 4±8 <0.001
Mitral valve insufficiency, none/mild 
over moderate to severe
41/0/0 0/10/7 <0.001
Aortic valve insufficiency, none/mild 
over moderate to severe
36/5/0 17/0/0 0.321
Serum creatinine, mg/dL 0.91±0.15 1.0±0.20 0.065
Hypertension 27 (66) 11 (65) 0.826
Dyslipidemia 8 (20) 3 (18) 0.839
Diabetes type 2 7 (17) 2 (12) 0.913
Coronary artery disease 1 (2) 2 (12) 0.419
Atrial fibrillation, paroxysmal 2 (5) 2 (12) 0.709
Atrial fibrillation, permanent 0 (0) 2 (12) 0.149
Medication ACE inhibitor 15 (37) 5 (29) 0.826
Medication β-blocker 20 (49) 10 (59) 0.683
Medication diuretics 12 (29) 5 (29) 0.760
Data are presented as total number (%) in case of categorical values and 
as mean±SD in case of numeric values. Significance of parameter differences 
between the 2 patient groups is given as P values. ACE indicates angiotensin-
converting enzyme; AS, aortic stenosis; BMI, body mass index; CI, cardiac in-
dex; CO, cardiac output; EDVI, end-diastolic volume index; EF, ejection fraction; 
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All model simulations were performed using MATLAB, 
Release R2011b (The MathWorks, Inc).
RESULTS
Model Calibration for the Normal Heart
Except for the maximal enzyme activities (Vmax values), 
which may vary owing to variable gene expression, the 
numeric values for all other parameters of the enzymatic 
rate laws were taken from reported kinetic studies of 
the isolated enzymes. Numeric values for the Vmax values 
 (Table S2) were estimated by the same procedure that 
was used for the calibration of our metabolic liver model19: 
calculated metabolite profiles and fluxes were adjusted 
to experimental data from independent experiments with 
perfused hearts and in vivo measurements whereas the 
metabolite concentrations were constrained to experi-
mentally determined ranges (Table S1). Short-term regu-
lation of key regulatory enzymes by the hormones insulin 
and catecholamines (epinephrine, norepinephrine) was 
included into the model by phenomenologic mathemati-
cal functions relating the enzyme’s phosphorylation state 
and the abundance of the GLUT4 transporter in the 
Figure 1. Reaction scheme of the metabolic model.
Arrows symbolize reactions and transport processes between compartments. A, Glycogen metabolism, (B) glycolysis, (C) oxidative pentose 
phosphate pathway in the endoplasmic reticulum and cytosol, (D) nonoxidative pentose phosphate pathway, (E) triglyceride synthesis, (F) synthesis 
and degradation of lipid droplets, (G) tricarbonic acid cycle, (H) respiratory chain and oxidative phosphorylation, (I) β-oxidation of fatty acids, (J) 
ketone body utilization, (K) glutamate metabolism, (L) mitochondrial electrophysiology (membrane transport of ions), and (M) utilization of branched-
chain amino acids. Small cylinders and cubes symbolize ion channels and ion transporters. Double arrows indicate reversible reactions, which, 
according to the value of the thermodynamic equilibrium constant and cellular concentrations of their reactants, may proceed in both directions. 
Reactions are labeled by the short names of the catalyzing enzyme or membrane transporter given in the small boxes attached to the reactions 
arrow. Metabolites are denoted by their short names. Full names and kinetic rate laws of reaction rates are outlined in Supplement S1. Full names 
of metabolites and a comparison of experimentally determined and calculated cellular metabolite concentrations are given in Table S1.
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sarcolemma to the plasma concentrations of glucose 
(insulin) and the exercise level (catecholamines; Supple-
ment S2). Model simulations, which correctly recapitulate 
metabolic measurements obtained with perfused hearts 
and in human in vivo studies, comprise glucose utilization 
at varying exogenous glucose concentrations; lactate uti-
lization and lactate/O2 ratio at varying exogenous lactate 
concentrations; utilization of free fatty acids (FFAs) at 
varying exogenous FFA concentrations; glucose utiliza-
tion in response to varying exogenous concentration of 
FFAs (glucose–FFA competition); KB utilization at vary-
ing exogenous β-hydroxybutyrate concentrations; utili-
zation rates of glucose, lactate, FFAs, KBs, and BCAA 
under postabsorptive resting conditions; and utilization 
rates of glucose, lactate, FFAs, KBs, and BCAAs at 
moderate pacing. Details of all validation simulations are 
given in Supplement S3 (including Figures S5–S10 and 
Tables S3–S8).
Figure 2 shows 2 model validations highlighting the 
good concordance of model predictions with experimen-
tal data. The examples demonstrate the ability of the 
heart to ensure cardiac functionality at varying cardiac 
workloads and varying plasma concentrations of energy 
substrates. In Figure 2A, the computed substrate uptake 
profile of the normal human heart is compared with the 
mean of experimental data taken from several in vivo 
studies.36–43 At rest, lactate is utilized with the highest 
rate, followed by FFAs and KBs. Counted in moles ATP 
per moles substrate (textbook values: glucose 38, lac-
tate 18, palmitate 138), FFAs represent the dominating 
energy source. At moderate pacing, the uptake of the 
carbohydrates is more than doubled, whereas the uptake 
of FFAs remains essentially unaltered. The energetic 
contribution of BCAAs was <1% at rest and pacing. Fig-
ure 2B shows the relationship between glucose uptake 
and plasma FFA concentration. The uptake rate of glu-
cose is suppressed with increasing levels of plasma FFAs 
by inhibition of glucose uptake44 ensuring the preferen-
tial utilization of fatty acids (Figure 2B).
Patient-Specific Model Calibration
For patient-specific model calibration, we used protein 
intensity profiles (defined through label-free quantifica-
tion intensities; see Methods) of 17 control hearts, 41 
patients with AS, and 17 patients with MVI. Using 2-di-
mensional liquid chromatography before tandem mass 
spectrometry analysis, we identified, in total, 9133 dis-
tinct protein groups, from which a subset of 321 proteins 
was used for model calibration.
Energetic Capacities of the LV of Controls and 
Patients With Valve Diseases
Figure 3 depicts the specific energetic parameters 
MVATP(rest), MVATP(max), and MAPR for each participant 
after 60-minute pacing. Compared with controls, the in-
dividual variations of these parameters were much larger 
for the 2 patient groups (see box plots in Figure 3B–3D). 
For patients with MVI, the mean value of the param-
Figure 2. Simulated and measured myocardial substrate uptake rates in vivo.
A, Substrate uptake rates at rest and at moderate pacing (50% maxVo2). (sim) Uptake rates were computed from reported extraction rates 
(1 – arterial concentration/concentration in coronary sinus) putting the coronary blood flow to 0.8 mL/min/g and heart weight to 300 grams. 
(exp) The data points represent the means of various experimental studies.37,38,40–43,45 B, Dependence of the glucose uptake rate from the plasma 
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eter MVATP(rest) was significantly higher (890±292 vs 
761±10 µmol/g/h), whereas MVATP(max) was significant-
ly lower when compared with control values (1713±245 
vs 1941±238 µmol/g/h; 2-sample Kolmogorov-Smirnov 
test). For patients with AS, the mean value of the parame-
ter MVATP(rest) was also significantly higher (800±270 vs 
761±10 µmol/g/h) and MVATP(max) was also significant-
ly lower (1513±257 vs 1941±238 µmol/g/h). For both 
groups of patients, the parameter MAPR was on average 
significantly lower compared with the controls (826±448 
in MVI and 904±340 in AS vs 1180±245 µmol/g/h). 
Hence, both groups of patients had on the average a re-
duced ATP production reserve, which was caused by in-
creased MVATP(rest) and decreased MVATP(max).
Substrate Uptake of Patients at Rest and at 
Maximal Workload
Next, we investigated changes in the substrate prefer-
ence of the LV accompanying altered metabolic capac-
ity (Figure 4). In the resting state, the largest differences 
occurred for the uptake rates of glucose and lactate for 
patients with MVI. Glucose uptake was increased by 
>20%. At rest, there was a significant decrease in lac-
tate utilization in patients with AS. In general, variances 
in substrate utilization rates were large, again pointing to 
individually differing metabolic phenotypes. The reduction 
in lactate utilization was significant also at maximal load 
in MVI and AS; glucose rates were significantly reduced 
only in patients with AS. Figure 4 also shows how the dif-
ferent substrates contribute to overall energy production. 
The contribution of fatty acids accounts for up to 2-thirds, 
whereas BCAAs always account for <1% of total energy 
expenditure and are therefore not shown.
Association of MVATP With Clinical Measures 
Evaluating the Mechanical Work and the 
Systolic Performance of the LV
In valve disease, the LV is exposed to chronic pressure 
load (AS) or volume overload (MVI). This results in a 
higher mechanical workload, which can be quantified by 
the surrogate internal myocardial power estimating the 
power of the LV required for cardiac contraction.35 Our 
analysis provided evidence for a strong correlation be-
tween tMVATP at rest and at maximal pacing and the inter-
nal myocardial power (Figure 5). A significant correlation 
of the energy parameters has also been found with the 
cardiac output (Figure 5). Taken together, these findings 
demonstrate a close association between increased ATP 
production capacity, increased mechanical work of the 
pressure/volume overloaded LV, and cardiac output.
Figure 3. MVATP(rest) and MVATP(max) for controls and patients with mitral valve disease and aortic stenosis.
A, Bottom values of the bars refer to MVATP(rest); top values refer to MVATP(max). The bar length indicates the myocardial ATP production reserve 
(MAPR=MVATP[max] – MVATP[rest]). B through D, Box plots showing mean values, upper and lower quartiles, and total span of MVATP(rest), 
MVATP(max), and MAPR for controls and patients with mitral valve insufficiency (MVI) and aortic stenosis (AS). Significant differences between 
the patient groups are indicated by connecting brackets with asterisks giving the significance level (*P<0.05, **P<0.01, ***P<0.001). A Bonferroni 
correction was applied to account for multiple testing. 
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Metabolic Profiling of Individual Patients
Despite the general trend of the energy parameters in 
the patients’ LV outlined in the preceding section, sub-
stantial differences in the metabolic profiles of individual 
patients occur. As an example, Figure 6 depicts the indi-
vidual energetic profiles of 3 patients with AS with large-
ly differing values of their cardiac energy parameters 
(Figure 3A). Patients A2 and A4 are characterized by 
impaired MAPR; patient A13 has a MAPR comparable to 
healthy hearts (Figure 3). The impaired MAPR of patient 
A2 results from an increased MVATP(rest) with a normal 
MVATP(max), whereas the impaired MAPR of patient A4 
results from an increased MVATP(rest) and a decreased 
MVATP(max). Patient A13 with a normal MAPR has nor-
mal MVATP(rest) and normal MVATP(max). The individual al-
terations in the energetics of the LV are also associated 
with marked differences in substrate utilization rates. For 
example, whereas patient A13 has normal MVATP(rest), 
resting carbohydrate utilization rates (glucose and lac-
tate) are strongly decreased and compensated by an in-
creased KB utilization rate. This increased KB utilization 
is also maintained at MVATP(max) and is even more pro-
nounced in patient A2. In contrast, patient A4 shows a 
decreased utilization rate for all substrates at MVATP(max).
Association of Preoperative Cardiac 
Metabolism With Postoperative Outcome
We also checked for a possible association between LV 
performance after valve surgery and the preoperative 
 metabolic status of the LV. A univariate rank correlation 
analysis revealed a statistically significant association be-
Figure 4. Contribution of energy-delivering substrates.
A and B, Relative contribution of the energy-delivering substrates to total energy expenditure at MVATP(rest) and MVATP(max) for the control group 
for 60 minutes pacing. Areas of the pie charts represent total energy expenditure. Changes of substrate uptake rates of patients with mitral valve 
insufficiency (MVI) or aortic stenosis (AS) relative to controls are shown at rest (C) and during maximal pacing (D). Plots show the relative change 
of substrate uptake rates of glucose (blue), lactate (orange), fatty acids (yellow), and ketone bodies (purple) for patients with MVI or AS during 
rest and at maximal ATP production rate after 60 minutes of pacing. Relative uptake rates are normalized to control values (ie, all control values 














December 14, 2021 Circulation. 2021;144:1926–1939. DOI: 10.1161/CIRCULATIONAHA.121.0556461934
Berndt et al CARDIOKIN1
tween change in New York Heart Association (NYHA) 
functional classification (ΔNYHA = NYHApostoperative – NY-
HApreoperative) and several metabolic capacities (Table S9), 
among them the maximal ATP production capacity in the 
postprandial state (P=0.02) and the maximal lactate up-
take rate (P=0.01). This indicates that preoperative meta-
bolic capability of the LV has an important effect on recov-
ery and might be used as a prognostic marker in the future.
Statistical Analysis
For the patient characteristics in the Table, significance 
of parameter differences between AS and MVI groups 
was evaluated by means of 2-sided, 2-sample Wilcoxon-
rank test in case of numeric data and χ2 test with Yates 
continuity correction in case of categorical data.
Statistical significances between patient groups in 
Figure 3 and Figure 4 were evaluated by means of non-
parametric Kolmogorov-Smirnov test. Statistical signifi-
cance in Figure 3 was corrected for multiple testing by 
means of Bonferroni correction.
Correlations in Figure 5 are given as Pearson linear 
correlation coefficients with P values indicating statistical 
significance of the correlation computed by means of the 
Student t test.
Correlations between presurgery and postsurgery dif-
ferences in NYHA Functional Classification and meta-
bolic capacities (Table S9) were evaluated by calculation 
of Spearman rank correlation coefficients with P values 
indicating statistical significance of the correlation com-
puted by means of the exact permutation test.
DISCUSSION
Novel Approach to Assess Myocardial ATP 
Producing Capacity
No method is available to measure MVATP in vivo. Invasive 
techniques, such as the determination of substrate extrac-
tion rates from coronary sinus, arterial concentration dif-
ferences, or the oxidation rates of 14C-labeled substrates 
from the rates of 14CO2, have been applied in healthy 
people and patients with heart diseases.36,37,46 However, 
such data cannot be directly converted into rates of ATP 
production. The same holds true for measurement of the 
myocardial oxygen consumption rate MVo2 reflecting the 
overall myocardial oxidative metabolism. The MVo2 does 
not capture the glycolytic ATP contribution, which is low 
under normoxic conditions but may increase 5-fold dur-
ing development of heart failure47 or even 20-fold during 
the transition from aerobic to anaerobic energy produc-
tion.48 Moreover, the ATP/O2 ratio may change consider-
ably with increasing workload owing to increasing car-
diac preference for carbohydrates. This makes it difficult 
to convert O2 consumption rates into ATP consumption 
rates. In addition, the maximal MVo2 can be low because 
Figure 5. Correlation between tMVATP(rest) and tMVATP(max) and internal myocardial power as well as cardiac output for patients 
with mitral valve insufficiency or aortic stenosis.
A through D, Patients with mitral valve insufficiency (MVI). E through H, Patients with aortic stenosis (AS). iMP indicates internal myocardial 
power; and CO, cardiac output. 
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of restrictions imposed to heart performance by the non-
metabolic factors. To close this methodologic gap, we ap-
plied a novel approach to assess to energetic capacity of 
the LV of the human heart by combining kinetic modeling 
with protein abundance data of metabolic enzymes de-
termined in cardiac tissue.
Reduced Myocardial Energetics in Patients With 
Valvular Disease
AS and MVI lead to chronic pressure or volume overload 
that result in phenotypically different myocardial remod-
eling (eccentric and concentric hypertrophy, respectively), 
both of which can progress to heart failure if left untreat-
ed. The cardiac adaptation processes to chronic overload 
conditions have been well characterized in terms of phe-
notyping and analysis of global cardiac function, but little 
is known about metabolic changes. The central findings 
of our approach are that even in patients with valvular 
dysfunction but preserved systolic function and no sign 
of heart failure, the energy metabolism is already deterio-
rated (Figure 3) and closely associated with mechanical 
power and systolic performance (Figure 5). The first find-
ing is in line with several studies (reviewed in Sankaral-
ingam and Lopaschuk),49 which have established that a 
reduction in the ATP production capacity already occurs 
in early phases of heart failure development. The second 
finding identifies the capability of the cardiac metabolic 
network to generate ATP as the key link between systolic 
function and energy metabolism of the LV rather than 
the intracellular transport capacity of energy-rich phos-
phates by the creatine kinase shuttle, which was found 
to not be significantly different in patients with AS with 
preserved and reduced systolic function.10
MVATP(rest) was significantly increased in the MVI and 
AS groups and MVATP(max) was significantly decreased 
in both groups, resulting in a significant reduction of 
the specific ATP production reserve MAPR (Figure 3). 
The general decrease of MVATP(max) in both groups of 
patients can be accounted for by a decrease of the oxida-
tive phosphorylation capacity as none of the investigated 
LVs showed excessive glycolytic activity. A decreased 
expression of the PGC-1α/PPARα transcription cas-
cade has been identified as an important mechanism 
responsible for downregulation of the oxidative phos-
phorylation in the failing myocardium.3
Our analysis revealed in both groups of patients a 
large variability of the energy parameters (Figures 3 
and 6), likely reflecting larger differences in the patient- 
specific functional and structural response of the LV 
to pressure/volume overload. Whereas some patients 
 present with signs of hypertrophy, myocardial thickening, 
and ventricular dilation, others may show alterations in 
contraction time or only modest signs of remodeling.50,51 
It is in the nature of our approach that the large interindi-
vidual variabilities in the computed metabolic parameters 
are exclusively attributable to individual variabilities in the 
abundance of metabolic enzymes and transporters, and 
Figure 6. Metabolic characterization of 3 patients with aortic stenosis.
On the left, relative substrate utilization rates are shown compared with healthy controls at rest (A) and at maximal load (C). On the right, relative 
contribution of the different substrates (glucose [blue], lactate [orange], fatty acids [yellow], and ketone bodies [purple]) to overall ATP production 
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these may be caused by individual differences in tran-
scription, translation, or proteolysis. In a recent study, it 
was found that LV with normal aortic valves and with AS 
and aortic insufficiency disease all exhibit unique tran-
scriptional profiles.52 Thus, it appears more likely that the 
observed metabolic heterogeneity is caused by small 
RNA variabilities, including microRNAs and small trans-
fer RNA fragments that can operate as modulators of the 
altered proteomics state.53,54
The large intraindividual variability of cardiac energet-
ics in patients with valvular dysfunction necessitates an 
individual assessment of the metabolic status (Figure 6).
Our study revealed a significant correlation between 
improvement in NYHA staging after valve surgery and 
a substantial number of preoperative metabolic capaci-
ties. In line with this, Pasquet et al55 identified cardiac 
glycolytic activity, assessed by means of 18-fluorodeoxy-
glucose positron emission tomography, as predictor of 
postoperative myocardial recovery after bypass surgery 
in patients with severe LV dysfunction. In principle, our 
approach allows inclusion of a large panel of metabolic 
capacities in the definition of novel risk predictors of 
postoperative outcome, but the additional benefit of such 
metabolic markers remains to be examined.
Alterations in the Myocardial Substrate 
Preference in Patients With Valvular Disease
Both groups of patients exhibited significant changes 
in myocardial use of the main energy substrates. There 
was a trend toward higher uptake rates for glucose and 
decreased uptake rates for lactate in patients with MVI 
and a decrease in glucose as well as lactate use in pa-
tients with AS. KB use rates showed high variability, but 
were generally increased in in patients with AS. This is 
in line with recent studies suggesting that increased re-
liance on KB metabolism offers a metabolic advantage 
in the failing heart and an ergogenic aid for exercise 
performance.56,57
Limitations of Our Approach
Our approach is restricted to the assessment of the en-
ergetic performance of an average cardiomyocyte work-
ing at fixed external concentrations of substrates and 
hormones. Hence, individual variances in circulating nu-
trients and hormones as well as activity-dependent con-
centration changes of oxygen and substrates attributable 
to changes of the coronary blood flow and the systemic 
metabolism (in particular skeletal muscle) were not taken 
into account. Moreover, it is well established that myocar-
dial blood flow is heterogeneous on the local level and 
that this heterogeneity in perfusion entails heteroge-
neity in the metabolic endowment of cardiomyocytes.58 
For example, Bach et al.59 demonstrated an association 
between heterogeneity of ventricular function and myo-
cardial oxidative metabolism in nonischemic dilated car-
diomyopathy. Thus, our analysis provides a comparison 
of metabolic capability under standardized conditions. 
The next step will be to incorporate the cellular meta-
bolic model into a tissue-scale model of myocardial me-
tabolism that includes local heterogeneity of blood flow, 
protein abundance, as well as individual plasma nutrient 
and hormone concentrations. Our previous work on liv-
er metabolism19,60,61 may serve as a paradigm for such 
a stepwise advancement of metabolic models from the 
cellular to the tissue level, but more in-depth data, such 
as histologic characterization and plasma metabolomics, 
will be required to enable such an approach.
Regarding the usefulness of our approach for the clin-
ical assessment of heart diseases, the need for protein 
abundance data is the decisive limiting factor, because 
endomyocardial biopsies are most commonly used in 
surveillance of allograft rejection in patients who undergo 
heart transplant.
Conclusions
We investigated 2 different cohorts (AS and MVI) with 
large biophysical differences in terms of ventricular re-
modeling but comparable clinical state and ventricular 
function. Our approach can unravel differences in the 
energetic state of the myocardium even in hearts that 
have similar clinical markers of hypertrophy and pump 
function. The proposed model-based approach extends 
our capabilities to gain deeper insight into metabolic al-
terations in different types of heart diseases.
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